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Several studies described an association between killer-cell immunoglobulin-like 
receptor (KIR)/HLA gene combinations and clinical outcomes in various diseases. In 
particular, an important combined role for KIR3DS1 and HLA-B Bw4-I80 in controlling 
viral infections and a higher protection against leukemic relapses in donor equipped 
with activating KIRs in haplo-HSCT has been described. Here, we show that KIR3DS1 
mediates positive signals upon recognition of HLA-B*51 (Bw4-I80) surface molecules 
on target cells and that this activation occurs only in Bw4-I80neg individuals, including 
those carrying particular KIR/HLA combination settings. In addition, killing of HLA-B*51 
transfected target cells mediated by KIR3DS1+/NKG2A+ natural killer (NK) cell clones 
from Bw4-I80neg donors could be partially inhibited by antibody-mediated masking of 
KIR3DS1. Interestingly, KIR3DS1-mediated recognition of HLA-B*51 could be better 
appreciated under experimental conditions in which the function of NKG2D was reduced 
by mAb-mediated blocking. This experimental approach may mimic the compromised 
function of NKG2D occurring in certain viral infections. We also show that, in KIR3DS1+/
NKG2A+ NK cell clones derived from an HLA-B Bw4-T80 donor carrying 2 KIR3DS1 
gene copy numbers, the positive signal generated by the engagement of KIR3DS1 
by HLA-B*51 resulted in a more efficient killing of HLA-B*51-transfected target cells. 
Moreover, in these clones, a direct correlation between KIR3DS1 and NKG2D surface 
density was detected, while the expression of NKp46 was inversely correlated with 
that of KIR3DS1. Finally, we analyzed KIR3DS1+/NKG2A+ NK cell clones from a HLA-B 
Bw4neg donor carrying cytoplasmic KIR3DL1. Although these clones expressed lower 
levels of surface KIR3DS1, they displayed responses comparable to those of NK cell 
clones derived from HLA-B Bw4neg donors that expressed surface KIR3DL1. Altogether 
these data suggest that, in particular KIR/HLA combinations, KIR3DS1 may play a role 
in the process of human NK cell education.
Keywords: human natural killer cells, activating killer-immunoglobulin-like receptors, Kir3Ds1, natural killer cell 
education, hla-B alleles, Kir/Kir-l interaction
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inTrODUcTiOn
Natural killer (NK) cells are lymphocytes of innate immunity that 
are involved in the host immune defenses against viruses and 
tumor cells. NK cells can exert cytotoxicity against transformed 
cells and release soluble factors important for regulating innate 
and adaptive immune responses (1, 2).
The NK cell function is controlled by an array of activating 
and inhibitory receptors, including the family of killer-cell 
immunoglobulin-like receptors (KIRs) (3). Inhibitory KIRs 
(iKIRs) possess a long cytoplasmic tail, containing ITIM motifs, 
responsible for the transduction of an inhibitory signal (3, 4), 
while activating KIRs (aKIRs) are characterized by a short tail and 
by a positively charged amino acid residue in their transmem-
brane region, which allows recruitment of the DAP12 signaling 
adaptor molecule (5, 6).
KIR3DL1/S1 is the KIR gene characterized by the highest 
degree of polymorphism, and it is the only one including alleles 
coding for either inhibitory (KIR3DL1) or activating (KIR3DS1) 
receptors. In particular, KIR3DL1 is highly polymorphic, 
whereas KIR3DS1*013 is the most represented in all examined 
populations (7). Notably, KIR3DS1 is the only activating receptor 
with three extracellular domains (8). Its inhibitory counterpart, 
KIR3DL1, recognizes HLA-A and HLA-B alleles, sharing the Bw4 
public epitope (3, 4, 9, 10). Despite the high degree of homology 
between these two KIR3D receptors, knowledge about KIR3DS1 
function and ligand specificity is not completely defined so far.
In this regard, several studies have suggested that certain 
HLA-B Bw4 alleles characterized by isoleucine in position 80 
(Bw4-I80) may be putative ligands for KIR3DS1. In particular, the 
carriage of a KIR3DS1 allele in conjunction with HLA-Bw4-I80 
alleles in patients with chronic HIV-1 infection has been associ-
ated with a slower progression to AIDS (11, 12). In addition, in 
individuals affected by acute HIV-1 infections and carrying HLA-
Bw4-I80 alleles, expansion of KIR3DS1+ NK cells (13), killing of 
HIV-1 infected cells, and inhibition of viral replication have been 
reported (12).
Carr and colleagues (14) could not detect any KIR3DS1-Fc 
binding to LCL721.221 cells transfected with HLA-B Bw4-I80 
alleles (HLA-B*57:01, HLA-B*58:01) or with HLA-B Bw4-T80 
(B*27:05) and HLA-Bw6 (B*15:02). Nevertheless they did not 
exclude the possibility that binding occurred below their detec-
tion limits or required the presence of additional factors, such as 
the presence of specific peptides in the HLA-B peptide-binding 
groove. In this regard, it has been shown that KIR3DS1 can inter-
act productively with HLA-Bw4 in the context of HIV infection. 
Indeed, two HIV-derived peptides have been described to enable 
HLA-B*57:01/KIR3DS1 interaction (15).
Recent studies have also reported that HLA-F open conform-
ers (OCs) are high-affinity ligands of KIR3DS1 and ligands of 
lower affinity for the inhibitory receptors KIR3DL1 and KIR3DL2 
(16, 17). However, KIR3DS1/HLA-F interaction cannot fully 
explain the control of HIV infection in KIR3DS1+ HLA-B Bw4-
I80+ patients only (16).
A protective role of KIR3DS1 in controlling certain tumors 
promoted by chronic viral infections has also been observed. 
For example, a protective effect of KIR3DS1 in combination with 
HLA-B Bw4-I80 alleles has been observed against hepatocellular 
carcinomas developed in chronically HCV-infected patients (18).
Remarkably, despite several attempts to define the specificity 
of KIR3DS1, the role of this receptor in the process of NK cell 
education has not been considered yet. In the present study, by the 
analysis of distinct NK clones, we show that certain self HLA-B 
allotypes can modify the functional responsiveness of KIR3DS1, 
thus providing evidence for an effect on the education of NK cells 
expressing this aKIR.
MaTerials anD MeThODs
KIR gene Profile and KIR-ligand  
(KIR-l) analyses
DNA of the tested donors was extracted using QIAamp DNA 
Blood Mini Kit (Qiagen, GmbH, Germany). The KIR gene profile 
and KIR-L analyses were performed using sequence-specific 
primer PCR (SSP-PCR) KIR genotyping kit and KIR ligand 
kit, respectively (GenoVision, Saltsjöbaden, Sweden) following 
the manufacture’s instruction. SSP-PCR analysis of KIR gene 
repertoire has been integrated with sequence of KIR3DL1 codon 
86 in order to distinguish KIR3DL1 alleles coding for surface 
receptors from those coding for polypeptide retained into the 
cytoplasm (19).
KIR3DL1 and KIR3DS1 gene copy 
number (gcn)
KIR3DL1 and KIR3DS1 GCN was measured using a quantitative 
PCR method and a comparative Ct method (ΔΔCt). The used 
amplification protocol, as well as primer and probe sequences, 
has been published by Jiang and coworkers (20). RNaseP was used 
as two copies reference gene (TaqMan Copy Number Reference 
Assay, human RNase P; Applied Biosystems).
HLA-B high-resolution Typing
Genomic DNA was used to perform HLA-B high-resolution 
typing. Some HLA typings were performed by sequence-based 
typing (SBT) using ATRIA kits according to the manufacturer’s 
instructions (Abbott–Celera Corporation, Alameda, CA, USA). 
Exons 2, 3, and 4 were bidirectionally sequenced using an ABI 
3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA), and the sequences were analyzed by Assign 3.5+ HARPS 
software (Conexio Genomics, Applecross, Australia). Some HLA 
typings were performed using sequence-specific oligonucleotide 
probes (PCR-SSOP; One Lambda, Canoga Park, CA, USA), 
and the results were analyzed by the software Fusion 3.0 (One 
Lambda, Canoga Park, CA, USA).
antibodies and Flow cytometry
The following mAbs, all produced in our lab, were used in this 
study: c218 (IgG1, anti-CD56), c127 (IgG1, anti-CD16), AZ20 
and F252 (IgG1 and IgM, respectively, anti-NKp30), BAB281 
and KL247 (IgG1 and IgM, respectively, anti-NKp46), Z231 
(IgG1, anti-NKp44), ON72 and BAT221 (IgG1, anti-NKG2D), 
KRA236 and F5 (IgG1 and IgM, respectively, anti-DNAM-1), 
11PB6 (IgG1, anti-KIR2DL1/S1), GL183 (IgG1, anti-KIR2DL2/
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L3/S2), ECM41 (IgM, anti-KIR2DL3), DF200 (IgG1, anti-
KIR2DL1/L2/L3/S1/S2/S5), FES172 (IgG2a, anti-KIR2DS4), z27 
(IgG1, anti-KIR3DL1/S1), AZ158 (IgG2a, anti-KIR3DL1/L2/
S1), Q66 (IgM, anti-KIR3DL2), z199 and Y9 (IgG2b and IgM, 
respectively, anti-NKG2A), 6A4 and A6/136 (IgG1 and IgM, 
respectively, anti-HLA-class I), D1/12 (IgG2a, anti-HLA-DR), 
5A10 (IgG1, anti-PVR), L14 (IgG2a, anti-Nectin-2), and BAM195 
(IgG1, anti-MICA). F278 (IgG1, anti-LIR-1/ILT2) mAb was 
kindly provided by Dr. Daniela Pende. Anti-NKG2C (IgG2b, 
134522 clone), anti-ULBP-1 (IgG2a, 170818 clone), anti-ULBP-2 
(IgG2a, 165903 clone), anti-ULBP-3 (IgG2a, 166510 clone), and 
anti-KIR2DL1-PE, -FITC, -APC, or non-conjugated (IgG1, 
143211 clone) mAbs were purchased from R&D System Inc. 
(Abingdon, UK). Anti-KIR2DL5-PE or non-conjugated (UP-R1 
clone), anti-KIR3DL1-FITC and -APC (DX9 clone) mAbs were 
purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). 
Anti-CD3-FITC (UCHT-1 clone), anti-CD56-PC7 (N901 clone), 
anti-NKG2A-APC (z199 clone), IgG1-PE (679.1Mc7 clone, 
isotype control), anti-KIR3DL1/S1-PE (z27 clone), and anti-
KIR2DL2/L3/S2-PC7 (GL183 clone) mAbs were purchased 
from Beckman Coulter Immunotech (Marseille, France). Anti-
KIR2DL2/L3-S2-FITC (CHL-clone) mAb was obtained from BD 
Bioscience Pharmingen (San Diego, CA, USA). Anti-HLA-Bw6-
FITC and anti-HLA-Bw4-FITC mAbs were purchased from One 
Lambda (Canoga Park, CA, USA). Anti-human HLA-E (IgG1, 
3D12 clone) and anti-human HLA-G (IgG1, MEM-G/9 clone) 
mAbs were purchased from BioLegend (San Diego, CA, USA) 
and Abnova (Taipei, Taiwan), respectively.
For cytofluorimetric analyses, cells were incubated with 
appropriate mAbs, followed by PE-, FITC-, or APC-conjugated 
isotype-specific goat anti-mouse secondary reagents (Southern 
Biotechnology Associated, Birmingham, AL, USA; Jackson 
ImmunoResearch Laboratories, Suffolk, UK) and/or fluoro-
chrome-conjugated mAbs. Cytofluorimetric analyses were 
performed on FACSCalibur (Becton Dickinson & Co., Mountain 
View, CA, USA), and data were analyzed by the CellQuest Pro 
software.
Mean fluorescence intensity ratios (MFIRs) were calculated by 
dividing the mean fluorescence intensity of stained molecules by 
the mean fluorescence of the respective isotype control.
generation of resting nK cells  
and nK cell clones
Buffy coats from healthy donors were obtained from the 
Immunohematology and Transfusion Center at the S. Martino 
Hospital (Genova, Italy). Approval was obtained by the ethical 
committee of IRCCS S. Martino-IST (39/2012) of Genova (Italy). 
Informed consent was provided according to the Declaration of 
Helsinki. Human peripheral blood mononuclear cells (PBMCs) 
were isolated by Ficoll/Hypaque gradients. PBMCs from 120 
healthy donors were screened for their KIR3DS1 expression by 
cytofluorimetric analysis. Donors characterized by the expression 
of a clearly detectable KIR3DS1+ NK cell subset (i.e., Z27+ DX9neg) 
were further typed for their KIR repertoires and KIR-Ls (n = 40 
donors). Based on KIR-L analysis, three groups of donors were 
selected: Bw4-I80 donors (n  =  12), Bw4-T80 donors (n  =  7), 
and Bw4neg donors (n  =  8). Individuals carrying both HLA-B 
Bw4-I80- and Bw4-T80-coding alleles were not considered in 
this study.
Highly purified NK  cells (97–99% purity) were isolated by 
depletion of non-NK cells, using Miltenyi NK Cell Isolation Kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany) from some of 
the selected KIR3DS1+ donors (two Bw4-I80, two Bw4-T80, and 
three Bw4neg donors). NK cells were cultured on irradiated feeder 
cells in the presence of 100 U/ml rhIL-2 (Proleukin; Chiron Corp., 
Emeryville, CA, USA) and 2 µg/ml phytoemagglutinin (PHA; Life 
Technologies, Paisley, UK) in round-bottomed 96-well microtiter 
plates to obtain activated polyclonal NK cell populations or, after 
limiting dilution, NK  cell clones as previously described (21). 
After 2–4 weeks of culture, the expanded NK cells were used for 
the phenotypic analysis and NK  cell cytotoxicity experiments. 
The relatively limited number of donors used to generate NK cell 
clones reflects the difficult collection of individuals with similar 
characteristics in terms of KIR and KIR-Ls. Only KIR3DS1+ 
NK  cell clones expressing the inhibitory receptor NKG2A as 
HLA-specific receptor and characterized by a sufficient growth to 
perform phenotypic and functional tests were selected and ana-
lyzed in the study. The number of KIR3DS1+/NKG2A+ NK cell 
clones used is indicated in the legends to the figures.
analysis of HLA-F Transcript
Total RNA was extracted from LCL721.221, C1R, C1R-B51, and 
JA3 cell lines using RNeasy mini kit (Qiagen) according to the 
manufacturer’s instruction, and cDNA synthesis was performed 
using oligo-dT primers. HLA-F transcript analysis was performed 
using Hs04193807_g1: HLA-F human kit (Applied Biosystems, 
Foster City, CA, USA). GAPDH transcript was used to normal-
ize the HLA-F quantity (Human GAPDH Endogenous Control 
Kit, Applied Biosystems, Foster City, CA, USA). The normalized 
HLA-F mRNA transcript of the tested samples was calculated as 
time-fold mRNA detected in the LCL721.221 cell line (chosen 
as reference in this study). Each cell line was analyzed in four 
independent experiments, and each reaction was performed at 
least in triplicate.
51cr cytolytic assays
The NK-mediated cytotoxicity was assessed in a 4-h 51Cr-release 
assay as previously described (22). Cells used as targets in the 
various cytolytic assays were the following: P815 (murine masto-
cytoma cell line), C1R (human EBV-transformed lymphoblastoid 
cell line), and C1R transfected with HLA-B*51 (Bw4-I80) allele 
(Figure S1 in Supplementary Material). For redirected killing 
assays, P815 were used as target cells in the presence of mAbs of 
IgG isotype at a concentration of 0.5 µg/mL. For masking experi-
ments, NK  cells were pre-incubated with mAbs specific to the 
various NK receptors 10 min before addition of target cells; mAb 
concentration was 10 µg/mL. The E:T ratios are indicated in the 
figure legends. Δ and Δ-B51 indicate the variations of C1R or 
C1R-B51 lysis in the absence or presence of anti-KIR3DS1 mAb 
calculated for each NK cell clone.
Three different types of NK cell clones were used as effector 
cells for cytolytic assays: (1) NKG2A+, KIR3DS1+, KIR2DL2/S2/
L3neg, KIR2DL1/S1neg, KIR3DL1neg, and NKG2Cneg; (2) KIR3DL1+, 
NKG2A+, KIR3DS1neg, KIR2DL2/S2/L3neg, KIR2DL1/S1neg, and 
FigUre 1 | Kir3Ds1 surface expression on resting peripheral blood natural killer (nK) cells. (a) Gate strategy for selecting KIR3DS1+ NK cell subset 
(CD3neg CD56+ KIR3DS1+ KIR3DL1neg) in peripheral blood mononuclear cell. For staining, the following mAbs were used in combination: anti-CD56 (N901), anti-CD3 
(UCHT-1), anti-KIR3DL1/S1 (z27), and anti-KIR3DL1 (DX9). (B) KIR3DS1 surface expression was evaluated on peripheral blood resting NK cells from HLA-B 
Bw4-I80 (n = 12, full squares), Bw4-T80 (n = 7, full circles), or Bw4neg (n = 8, full triangles) healthy donors in terms of frequency, mean fluorescence intensity ratio, 
and median values. Summarized results are compared in three scatter dot plots, respectively. In each plot, average and standard deviation are represented.
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NKG2Cneg; and (3) KIR3DL1neg, NKG2A+, KIR3DS1neg, KIR2DL2/
S2/L3neg, KIR2DL1/S1neg, and NKG2Cneg.
statistical analysis
Wilcoxon–Mann–Whitney non-parametric tests were employed. 
The statistical significances (p value: *p  <  0.1, **p  <  0.01, 
***p < 0.001) are indicated. Graphic representations and statisti-
cal analysis were performed using GraphPad Prism 6 (GraphPad 
Software, La Jolla, CA, USA).
resUlTs
Kir3Ds1 surface expression on resting 
nK cells is not affected by Differences in 
hla-B allotypes
Healthy donors were screened for their KIR3DS1 expression by 
cytofluorimetric analysis. To distinguish between KIR3DS1+ and 
KIR3DL1+ cells, peripheral blood NK cells were stained in double 
fluorescence analysis with two different mAbs: an anti-KIR3DL1-
specific mAb (clone DX9) and an mAb specific for both KIR3DL1 
and KIR3DS1 (clone Z27) (Figure 1A). Donors characterized by 
the expression of a KIR3DS1+ NK cell subset (i.e., Z27+ DX9neg) 
were further typed for their KIR repertoires and KIR-Ls (Figure 
S2 in Supplementary Material).
KIR gene analysis allowed us to define the telomeric regions of 
the tested donors. In order to compare donors characterized by 
similar KIR3DL1/3DS1 locus, we restricted our analysis to TelA/
TelB donors, namely, individuals characterized by one KIR3DL1 
and one KIR3DS1 gene copy. KIR3DL1neg donors (i.e., individuals 
characterized by two B telomeric regions) were excluded from 
this study according to recent evidences showing hyporespon-
sive and less frequent KIR3DS1+ NK cells in this type of donors 
(23). Subsequently, based on KIR-L analysis, three groups of 
donors were selected: (a) Bw4-I80 donors, typed as Bw4-I80pos 
and Bw4-T80neg (including both Bw4-I80/Bw4-I80 and Bw4-
I80/Bw6 donors); (b) Bw4-T80 donors, typed as Bw4-T80pos  
and Bw4-I80neg (including both Bw4-T80/Bw4-T80 and Bw4-
T80/Bw6 donors); and (c) Bw4neg donors, lacking both Bw4-I80 
and Bw4-T80. Individuals carrying both HLA-B Bw4-I80- and 
Bw4-T80-coding alleles were not considered in this study. Also 
some HLA-A molecules are characterized by a Bw4-80I motif 
(e.g., HLA-A*23, -A*24, -A*25 or -A*32) (24), and their frequency 
in the European population is ~16% (http://www.ncbi.nlm.nih.
gov/gv/mhc/ihwg.cgi?ID=9&cmd=PRJOV). Nevertheless, since 
not all HLA-A Bw4-I80 molecules are KIR3DL1 ligands (10, 25), 
we restricted our analyses to HLA-B alleles with Bw4-I80.
Comparison of KIR3DS1 surface expression on resting 
NK cells derived from these three donor groups did not show any 
significant difference in terms of percentage, MFIR, and median 
values (Figure 1B). These data are in line with previous results 
showing no substantial differences in KIR3DS1 mRNA levels 
between HLA-B Bw4-I80 and HLA-Bw6 healthy individuals (13).
Thus, similar to what had already been demonstrated for 
HLA-C alleles in relation to KIR2DS1 (26), expression of differ-
ent HLA-B allotypes does not influence the overall frequency of 
KIR3DS1+ NK cells and the KIR3DS1 surface expression density 
in peripheral blood NK cells.
Phenotypic and Functional Differences  
in Kir3Ds1+/nKg2a+ nK cell clones 
Derived from Donors carrying Various 
hla-B allotypes
Several NK cell clones were generated from donors belonging to 
each of the three above-mentioned groups (Bw4-I80: SiCa and 
J76 donors, Bw4-T80: J13 donor, and Bw4neg: GL115 and U58 
donors). These donors were all characterized by a TelA/TelB 
KIR genotype, nevertheless, since KIR haplotype characterized 
by KIR3DL1/3DS1 duplication has been described (20, 27), 
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GCN analysis was performed to verify, in these five donors, the 
presence of one KIR3DL1 and KIR3DS1 copy (Figure  2). To 
exclude the potential educational effects of different KIR/KIR-L 
interactions on KIR3DS1 expression and function, KIR3DS1+ 
NK cell clones expressing the inhibitory receptor NKG2A as the 
only known HLA-specific receptor were selected.
As shown in Figure 2A (left panel), cytofluorimetric analysis 
revealed that KIR3DS1 expression was significantly heterogene-
ous among NK cell clones derived from individuals with different 
HLA-B allotypes. Indeed, NK cell clones derived from Bw4-I80 
donors, and to a lower extent those from Bw4-T80 donors, showed 
a reduced expression of KIR3DS1 as compared to NK cell clones 
derived from Bw4neg donors (***p  <  0.0001 and **p  =  0.0018, 
respectively). On the contrary, no differences in NKG2A surface 
expression could be detected among the same series of NK cell 
clones analyzed (not shown).
KIR3DS1+/NKG2A+ NK cell clones were then analyzed in redi-
rected killing assays using mAbs specific for several activating or 
inhibitory receptors. Notably, the magnitude of cytolytic responses 
to KIR3DS1 mAb-mediated triggering correlated with the levels of 
KIR3DS1 surface expression. In particular, as shown in Figure 2B 
(left panel), NK  cell clones from Bw4-I80 donors expressing a 
significantly lower KIR3DS1 MFIR displayed a reduced incre-
ment of cytotoxicity upon KIR3DS1 mAb-mediated cross-linking 
as compared to those derived from Bw4neg donors (*p = 0.0287). 
On the contrary, mAb-mediated triggering of other activating 
receptors, including NKp46, CD16 (Figure 2B, left panel), NKp30, 
NKp44, NKG2D, and DNAM-1 (not shown), did not display any 
significant variation between KIR3DS1+ NK cell clones derived 
from Bw4-I80 and those derived from Bw4neg donors. Notably, the 
expression of these (non-HLA-specific) activating receptors did 
not display any significant difference in KIR3DS1+ NK cell clones 
derived from Bw4-I80 or Bw4neg donors (Figure 3).
Phenotypic and Functional analysis of 
Kir3Ds1+/nKg2a+ nK cell clones from 
Donors with Peculiar KIR3DL1/S1 and 
HLA-B combinations
Considering that it has been shown that the number of KIR3DL1 
and KIR3DS1 gene copies plays an important role in modulating 
the HIV-1 control and that this effect seems to be detectable 
only after epistatic interactions between HLA molecules and 
KIRs (23, 28), we extended the phenotypic and functional 
analyses to additional NK cell clones derived from donors with 
peculiar KIR3DL1/S1 and HLA-B combinations [Figures 2A,B 
(right panels) and Figure 2C]. In particular, NK cell clones were 
derived from: (a) an HLA-B Bw4-T80/Bw6 donor equipped 
with 2 KIR3DS1 and 1 KIR3DL1 GCN (P61, referred to as T80-
3DS1-2GCN); (b) an HLA-B Bw4-T80/Bw6 donor carrying 
HLA-B*37:01, a particular Bw4-T80 allotype characterized by 
D77-T80 sequence (K9, referred to as HLA-B*37:01); and (c) 
an HLA-Bw4neg donor equipped with a KIR3DL1 allele coding 
for a polypeptide retained into the cytoplasm (K7, referred to as 
Bw4neg KIR3DL1intra) (29). As shown in Figure 2A (right panel), 
comparison of KIR3DS1 MFIR among NK cell clones of this sec-
ond set (T80-3DS1-2GCN, HLA-B*37:01, Bw4neg KIR3DL1intra 
donors) did not reveal significant differences. On the contrary, 
some differences could be detected by comparing the first and 
the second set of donors analyzed. As shown in Figure  2A, 
KIR3DS1+ NK cell clones derived from T80-3DS1-2GCN donor 
displayed a more heterogeneous KIR3DS1 surface expression as 
compared to NK cell clones derived from T80 donor carrying 
one KIR3DS1 GCN. Nevertheless, NK cell clones derived from 
T80-3DS1-2GCN donor (but also those from B*37:01 donor) did 
not display significant differences in terms of KIR3DS1 MFIR as 
compared to NK clones of the first set.
On the contrary, NK cell clones from the Bw4neg KIR3DL1intra 
donor displayed a significantly lower KIR3DS1 surface expres-
sion (***p < 0.0001) (Figure 2A) but a similar cytotoxicity upon 
KIR3DS1 mAb-mediated triggering (Figure 2B) as compared to 
NK  cell clones derived from Bw4neg donors expressing surface 
KIR3DL1.
Moreover, the comparison of the cytotoxicity in redirected 
killing assays between the first and second sets of donors revealed 
that NK cell clones derived from the second set were character-
ized by higher increments of cytotoxicity upon KIR3DS1 mAb-
mediated triggering than NK cell clones from Bw4-I80 donors 
(*p  =  0.0243 with T80-3DS1-2GCN donor, *p  =  0.0014 with 
HLA-B*37:01 donor, and **p = 0.0059 with Bw4neg KIR3DL1intra 
donor) (Figure 2B).
correlation analysis between expression 
of Kir3Ds1 and non-hla-specific 
activating receptors in Donors 
characterized by Different hla-B 
allotypes
The existence of a possible correlation between the expression 
of KIR3DS1 and that of relevant non-HLA-specific activating 
receptors (i.e., NCRs, NKG2D and DNAM-1) was analyzed in 
all KIR3DS1+/NKG2A+ NK cell clones considered in the present 
study. Of interest, only in T80-3DS1-2GCN donor, KIR3DS1 
surface density correlated inversely with NKp46 and directly 
with NKG2D MFIR (*p = 0.0154 and *p = 0.0107, respectively) 
(Figure 4). Notably, this result was detected only in NK cell clones 
from these donors characterized by higher and heterogeneous 
values of KIR3DS1 MFIR (Figure  2A, right panel). Based on 
this observation, it cannot be ruled out that, in given HLA/KIR 
haplotype settings, KIR3DS1 may influence the surface density of 
NKp46 and NKG2D.
Kir3Ds1-Mediated recognition of 
hla-B*51 allele on Transfected cells
According to previous data suggesting a possible interaction 
between KIR3DS1 and HLA-B Bw4-I80 alleles (30) and consider-
ing the high level of homology between the extracellular domains 
of KIR3DS1 and KIR3DL1 as well as the ability of KIR3DL1 to 
recognize in most instances HLA-B Bw4-I80 alleles with higher 
efficiency than HLA-B Bw4-T80 alleles (9, 25), all KIR3DS1+/
NKG2A+ NK cell clones were assessed for their capability of kill-
ing HLA-B Bw4-I80 target cells. In particular, the killing activity 
of KIR3DS1+/NKG2A+ NK cell clones was assessed against the 
C1R cell line transfected or not with HLA-B*51 allele (31).
FigUre 2 | Kir3Ds1 surface expression and mab-mediated cross-linking of Kir3Ds1 in Kir3Ds1+/nKg2a+ natural killer (nK) cell clones. KIR3DS1+/
NKG2A+ NK cell clones derived from HLA-B-typed donors were analyzed for KIR3SD1 surface expression (a) and for 51Cr release in redirected killing assay against 
P815 cell line (B). Data related to HLA typing and surface/intra KIR3DL1 presence are indicated in the box below panel (B). (a) The NK cell clones of the first set (left 
panel) were derived from Bw4-I80 (n = 10, full square), Bw4-T80 (n = 9, full circle), and Bw4neg (n = 12, full triangles) donors, whereas NK cell clones of the second 
set (right panel) were derived from T80-3DS1-2GCN (n = 11, overturned full triangle), HLA-B*37:01 (n = 10, full rhombus), and Bw4neg KIR3DL1intra (n = 12, full star) 
donors. (B) The cytolytic activity of the first (left panel) and second (right panel) set of KIR3DS1+/NKG2A+ NK cell clones was evaluated in redirected killing assays 
upon mAb-mediated cross-linking of different NK receptors. Cytolytic assays were performed in the absence of mAbs (white bar) or in the presence of anti-CD16 
(c127, dark gray bar), anti-NKp46 (BAB281, light gray bar), or anti-KIR3DS1 (z27, black bar) mAbs. Average, standard deviation, and p values are indicated 
(*p < 0.1, **p < 0.01, and ***p < 0.001). (c) HLA-B typing, KIR3DL1, and KIR3DS1 gene copy number (GCN) analyses of the indicated donors are shown. 
&P: indicated a group of alleles with identical sequence at exons 2 and 3 and therefore sharing the same antigen-binding domains.
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FigUre 3 | surface expression of several non-hla-specific activating 
receptors. Staining of NKp46 (BAB281), NKp30 (AZ20), NKp44 (z231), 
NKG2D (ON72), and DNAM-1 (KRA236) molecules on KIR3DS1+/NKG2A+ 
natural killer (NK) cell clones derived from Bw4-I80 (n = 12, full squares) or 
Bw4neg carrying surface KIR3DL1 (n = 13, full triangles) donors were 
compared in terms of mean fluorescence intensity ratio (MFIR) in scatter dot 
plot representation. Average and standard deviation are shown.
FigUre 4 | Phenotypic analyses of Kir3Ds1+/nKg2a+ natural killer (nK) cell clones derived from T80-3Ds1-2gcn donor. Correlation analyses among 
NKp46 or NKG2D activating receptors and KIR3DS1 surface expression in several KIR3DS1+/NKG2A+ NK cell clones (n = 8) derived from a T80-3DS1-2GCN donor 
are represented. Linear regression values (r) and p values are shown.
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Considering recent studies showing that HLA-F OCs are high-
affinity ligands of KIR3DS1 (16, 17), the HLA-F transcript was 
analyzed in C1R and C1R-B51 target cells to assess whether these 
cells would express this KIR3DS1 ligand. JA3 (a Jurkat clone) 
(32) and LCL 721.221 cell lines were used as negative control 
and positive control, respectively (16, 33). As shown in Figure 5 
and Figure S3 in Supplementary Material, C1R and C1R-B51 
expressed very low levels of HLA-F transcript similar to JA3 cells, 
whereas LCL 721.221 expressed HLA-F mRNA five times more 
than C1R-B51. Thus, possible differences of lysis between C1R 
and C1R-B51 may not be attributed to recognition of HLA-F by 
KIR3DS1.
A representative cytolytic experiment against C1R/C1R-
B51 target cells performed using as effector cell a KIR3DS1+/
NKG2A+ NK  cell clone derived from the T80-3DS1-2GCN 
donor is shown in Figure 6. As controls, KIR3DS1neg/NKG2A+ 
and KIR3DL1+/NKG2A+ NK cell clones derived from the same 
donor were analyzed. In the absence of mAbs, C1R-B51 cells were 
killed slightly more efficiently than un-transfected C1R by the 
KIR3DS1+/NKG2A+ NK cell clone (*p = 0.0159). Notably, this 
difference of lysis was abolished upon mAb-mediated masking 
of KIR3DS1, suggesting a possible positive recognition of HLA-
B*51 by KIR3DS1 (Figure 6A). Interestingly, this result was more 
evident when the experiment was performed in the presence of 
anti-NKG2D mAb. Thus, as shown in Figure 6B, the difference 
between C1R and C1R-B51 killing was amplified by NKG2D 
mAb-mediated blocking (**p  =  0.0022). Importantly, further 
masking of KIR3DS1 abrogated this difference (**p  =  0.0065) 
(Figure 6B). Similar data were obtained upon additional mAb-
mediated masking of NKG2A.
A similar experimental approach was applied to the NK cell 
clones generated from the other donors analyzed (Figure  7). 
These clones were characterized by a substantially homogeneous 
NKG2D expression. The cytolytic assays were performed not 
only in the presence of blocking NKG2D but also upon mAb-
mediated masking of NKG2A in order to further reduce possible 
functional variations caused by different intensities of inhibitory 
signals consequent to NKG2A/HLA-E interaction. Then, cyto-
toxicity was evaluated upon additional blocking of KIR3DS1 
(Figure 7). In this set of experiments, in order to better appreciate 
the KIR3DS1 contribution to target killing, each NK cell clone 
was also analyzed for possible variations in the lysis of C1R or 
C1R-B51 targets in the absence or in the presence of KIR3DS1 
mAb-mediated blocking (ΔC1R and ΔC1R-B51).
In Bw4-I80 donors, lysis of C1R and C1R-B51 was not affected 
by the addition of anti-KIR3DS1 mAb (as shown by the raw data 
as well as ΔC1R and ΔC1R-B51 values) (Figure  7A). On the other 
hand, in Bw4neg donors, the addition of anti-KIR3DS1 mAb 
slightly decreased C1R-B51 killing and a significant gap between 
ΔC1R and ΔC1R-B51 could be detected (*p = 0.0188).
KIR3DS1+/NKG2A+ NK cell clones from the T80-3DS1-2GCN 
donor killed more efficiently C1R-B51 than C1R. Moreover, 
the addition of anti-KIR3DS1 mAb abolished this difference. 
Remarkably, in this donor, the comparison between ΔC1R and 
ΔC1R-B51 showed a highly significant difference (***p  <  0.0001, 
Figure 7B). Significant differences between ΔC1R and ΔC1R-B51 could 
also be observed in KIR3DS1+/NKG2A+ NK cell clones derived 
from both HLA-B B*37:01/Bw6 and Bw4neg KIR3DL1intra donors 
FigUre 6 | Killing of c1r-B51 target cells by natural killer (nK) cell clones derived from a T80-3Ds1-2gcn donor. Three representative NK cell clones 
(one KIR3DS1neg/NKG2A+, one KIR3DS1+/NKG2A+ and one KIR3DL1+/NKG2A+) derived from the T80-3DS1-2GCN donor were tested for cytotoxic activity against 
C1R (dark gray histograms) and C1R-B51 (light gray histograms) target cell lines. Experiments were performed in the absence (a) or in the presence of anti-NKG2D 
masking mAb (B). Additional mAb-mediated maskings were carried out as indicated below panel B. Histograms summarized results of three independent 
experiments in duplicate. Average, standard deviation, and p values are shown (*p < 0.1 and **p < 0.01).
FigUre 5 | c1r and c1r-B51 express low level of HLA-F transcript. 
HLA-F mRNA amount detected in the analyzed cell lines has been 
normalized to GAPDH transcript. The normalized HLA-F mRNA transcript of 
the tested cell lines was calculated as time-fold the mRNA detected in 
LCL721.221 cell line (chosen as reference). Mean values obtained in four 
different experiments and their standard deviations are reported.
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(**p = 0.0073 and *p = 0.0110, respectively). All together, these 
data suggest a direct involvement of KIR3DS1 in the recognition 
of HLA-B*51 (Bw4-I80) target cells. Remarkably, this result can 
be detected only when NK  cells were generated in particular 
KIR/HLA combination settings. Indeed, KIR3DS1-mediated 
recognition of HLA-B*51 occurs only when NK cell clones were 
derived from Bw4-I80neg donors (Bw4-T80-2GCN, B*37:01/Bw6, 
or Bw4neg), suggesting a role for HLA-B/KIR3DS1 interaction in 
the process of NK cell education.
Notably, when comparing KIR3DS1+/NKG2A+ and 
KIR3DS1neg/NKG2A+ NK  cell clones, a significant difference 
in NKp46 surface expression was observed only in Bw4-I80 
donors. Thus, KIR3DS1+/NKG2A+ NK  cell clones expressed 
lower levels of NKp46 than KIR3DS1neg/NKG2A+ NK  cell 
clones (***p = 0.0005), further corroborating the possibility that 
HLA-B/KIR3DS1 interaction may be involved in the process of 
NK cell education (Figure 8).
DiscUssiOn
A number of studies described an association between given 
KIR/HLA gene combinations and clinical outcome in various 
immune challenges and reported a possible perturbation of KIR/
HLA interactions by the presented peptide. In particular, an 
important combined role played by KIR3DS1 and HLA-B Bw4-
I80 in controlling HIV infection (11, 12) and the recognition of 
specific HIV-derived peptides associated with HLA-B*57 alleles 
by KIR3DS1 have been described (15).
In the present study, we provided the first evidence of a direct 
involvement of KIR3DS1 in the NK-mediated recognition of 
HLA-B*51 surface molecules expressed on target cells. This 
capability is manifested only when KIR3DS1 is expressed by 
NK cells derived from individuals carrying particular KIR/HLA 
combinations. Although our study was performed on a limited 
number of donors (due to the difficulty in the collection of indi-
viduals with similar characteristics in terms of KIR and KIR-Ls 
as well as in the generation and expansion of appropriate NK cell 
clones), our results suggest a role for this activating receptor in 
the process of NK  cell education. In particular, the KIR3DS1-
mediated positive recognition of HLA-B*51 (Bw4-I80) could be 
detected in NK cell clones derived from Bw4-I80neg donors (one 
Bw4-T80-2GCN, one B*37:01/Bw6, and three Bw4neg) but not 
in those from Bw4-I80 donors (two donors). Thus, in a manner 
reminiscent of that previously described for KIR2DS1 (26, 34), 
the interaction of KIR3DS1 with its self-HLA-B class I ligand 
(Bw4-I80 alleles) would affect the subsequent response mediated 
by this aKIR. Indeed, in HLA-B Bw4-I80 donors, the process of 
NK  cell education that is taking place via NKG2A/self-HLA-E 
FigUre 7 | c1r-B51 killing by Kir3Ds1+/nKg2a+ natural killer (nK) cell clones. NK cell clones were tested in 51Cr-release cytotoxicity assay against C1R 
(circle) and C1R-B51 (square) target cell lines in the presence of anti-NKG2D + anti-NKG2A masking mAbs (full symbols) or anti-NKG2D + anti-NKG2A + anti-
KIR3DS1 masking mAbs (empty symbols). Δ and Δ-B51 indicate the variations of C1R or C1R-B51 lysis in the absence or presence of anti-KIR3DS1 mAb for each 
NK cell clone. NK cell clones derived from Bw4-I80 (n = 11) and Bw4neg (n = 9) donors are represented in panel (a), whereas those derived from T80-3DS1-2GCN 
(n = 9), HLA-B*37:01 (n = 9), and Bw4neg KIR3DL1intra (n = 8) donors are represented in panel (B). Plots summarized results of three independent experiments in 
duplicate. p values indicate a statistically significant difference between the groups (*p < 0.1, **p < 0.01, and ***p < 0.001).
FigUre 8 | nKp46 surface expression on Kir3Ds1+/nKg2a+ and 
Kir3Ds1neg/nKg2a+ natural killer (nK) cell clones derived from 
Bw4-i80 or Bw4neg donors. KIR3DS1+/NKG2A+ (full symbols) and 
KIR3DS1neg/NKG2A+ (empty symbols) NK cell clones derived from Bw4-I80 
(squares, n = 12 and n = 19, respectively) and Bw4neg (triangles, n = 13 and 
n = 22 respectively) donors were stained with anti-NKp46 mAb (BAB281). 
Results are summarized in scatter plot analysis. Average, standard deviation, 
and p values are indicated (***p < 0.001).
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interaction is characterized by a decrement in NK cell responsive-
ness upon KIR3DS1 engagement, thus ensuring self-tolerance. In 
this context, it has to be considered that KIR3DS1 responsiveness 
in redirected killing assays was lower in Bw4-I80 than in Bw4-
I80neg donors. In particular, among those analyzed, KIR3DS1 was 
the only receptor showing a significant differential expression and 
responsiveness between Bw4-I80 and Bw4neg donors.
The analysis performed in the present study was limited to 
KIR3DS1+/NKG2A+ NK cell clones in order to evaluate whether 
KIR3DS1 expression could confer alloreactivity to non-alloreactive 
NKG2A+ NK cells and to minimize the effect that other self KIR/
HLA interactions would exert on NK cell education. Several studies 
have suggested that, in given donor/recipient pairs, the expression 
of aKIRs, such as KIR2DS1, can amplify the size of the alloreactive 
NK cell subset. This effect is particularly relevant in the successful 
therapy of high-risk acute leukemias in the haplo-HSCT setting 
(35–39). Indeed, it has been shown that the “non-alloreactive” 
NKG2A+ iKIRsneg NK  cells can display alloreactivity against 
HLA-C2+ recipient cells when they co-express KIR2DS1 (40). A 
similar effect could be true, at least in part, also for KIR3DS1. In 
this context, the definition of the specificity/function of KIR3DS1 
would have important implications not only to identify donors 
capable of generating alloreactive NK  cells (on the basis of the 
existence of a KIR/HLA-class I mismatch) but also to select the 
best donor, according to the size of the alloreactive NK cell subset.
On the basis of a recent study (23) showing that KIR3DL1-
dependent licensing of NK cells could be involved in shaping a 
strong antiviral response mediated by KIR3DS1+ NK  cells, we 
also analyzed KIR3DS1 expression and responsiveness in donors 
characterized by peculiar KIR/HLA combinations. In this context, 
we showed that KIR3DS1 mAb-mediated triggering of cytotoxic-
ity in NK cell clones from a Bw4neg donor carrying KIR3DL1intra 
is similar to that detectable in NK cell clones from Bw4neg donors 
expressing surface KIR3DL1. It is noteworthy that this increment 
of cytotoxicity occurred despite the low surface expression of 
KIR3DS1 (Figure 2). Remarkably, NK cell clones from the Bw4neg 
donor carrying KIR3DL1intra were able to kill HLA-B*51+ target 
cells with efficacy comparable to that of NK cell clones derived 
from Bw4neg donors with surface KIR3DL1.
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Moreover, different from KIR3DS1+ NK cell clones of classical 
HLA-B Bw4-T80 donors, clones derived from a donor carrying 
the HLA-B*37 allele (a particular HLA-Bw4-T80 allotype char-
acterized by the D77-T80 sequence) were characterized by higher 
KIR3DS1 responsiveness in redirected killing assays and higher 
efficiency of killing HLA-B51+ target cells as compared to NK 
clones from HLA-B Bw4-I80 donors.
However, the highest increment of cytotoxicity against C1R-
B51 cells was detected in NK cell clones from a T80-Bw4 donor 
carrying two copies of KIR3DS1 and one copy of KIR3DL1. 
Interestingly, in this donor, an inverse correlation between 
KIR3DS1 and NKp46 MFIR could also be detected. This finding is 
relevant in the context of NK cell education. Indeed, a low surface 
expression of NKp46 combined with high KIR3DS1 surface den-
sity on NK cell clones may prevent possible KIR3DS1-mediated 
autoreactive responses in non-pathological conditions. In the 
same donor, a direct correlation between KIR3DS1 and NKG2D 
surface expression was also observed. Notably, these correlations 
could be observed only in NK clones from this donor in which 
KIR3DS1 surface expression was more heterogeneous and higher 
as compared to Bw4-T80 donor carrying one copy of KIR3DS1 
and one copy of KIR3DL1.
The direct correlation between KIR3DS1 and NKG2D surface 
expression is particularly interesting if we consider that NKG2D 
pathway is less functional in certain viral infections. Indeed, pre-
vious studies have described that several viral immune evasion 
strategies possibly evolved to elude NKG2D-mediated immune-
surveillance (30, 41–44). For example, the HIV Nef protein 
prevents the expression of some NKG2D ligands at the surface 
of infected cells (45, 46). According to these data, in an attempt 
to simulate the compromised NKG2D function occurring during 
certain viral infections, we analyzed the effect of mAb-mediated 
NKG2D blocking in KIR3DS1+ NK clones. Thanks to this experi-
mental approach, we could show that KIR3DS1 function may be 
crucial, primarily during viral infections in which other trigger-
ing signals, such as those through NKG2D, are compromised. In 
this context, it is also important to take into consideration that 
the expression of HLA-B can be modified only marginally during 
certain viral infections. Thus, in HIV-1-infected viremic patients, 
while HLA-A and -Bw6 surface molecules were significantly 
downmodulated in T cell blasts, HLA-B Bw4 alleles were not (47).
Considering the “discontinuity theory for immunity” (48), 
it is also possible that KIR3DS1+ NK cells in donors expressing 
specific HLA class I (Bw4-I80) may be less responsive under 
normal conditions. However, when a non-physiologic trigger-
ing signal is given to the cells (e.g., viral infections), the equi-
librium that is maintaining tolerance could be disrupted and 
may become an important component of an efficient immune 
response (34). This mechanism could explain the association 
between the expression of KIR3DS1 in conjunction with HLA-B 
Bw4-I80 in patients with chronic HIV-1 infection and a slower 
progression to AIDS.
KIR3DS1 associates DAP12 ITAM-bearing molecules in 
its cytoplasmic tail to enable signal transduction. Surprisingly, 
in recent years, different studies showed that ITAMs can also 
generate an inhibitory signal in addition to the activating ones. In 
particular, the same ITAM-coupled receptors can generate both 
positive and negative signals (49–51). The molecular basis of this 
dual function is not well understood at the present; however, it 
has been suggested that the avidity of receptor ligation may define 
the nature of response. In this regard, one may speculate that the 
peptide in the HLA-Bw4-I80 groove could determine change of 
affinity of KIR3DS1 ligation. Thus, healthy self peptides could 
mediate a low-affinity, tolerogenic signal, whereas viral peptides 
(i.e., HIV derived) would allow high-affinity activating signals. 
This hypothesis would be in line with the protective effect exerted 
by the combined presence of KIR3DS1 and HLA-B Bw4-I80 in 
patients with chronic HIV-1 infection.
All these considerations are consistent with an important role 
of KIR3DS1 in the control of viral infections (8, 30), primarily 
in post-transplantation settings (52). Since transplantation from 
donors displaying NK-cell alloreactivity and expressing KIR2DS1 
and/or KIR3DS1 has been associated with a reduced risk of no 
relapse mortality, that is largely infection related, and with 
significantly better event-free survival (38, 53), our results could 
further improve the selection of the most suitable donor, taking 
into account the expression of not only KIR3DS1 but also the self 
HLA-B allotype expressed.
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